(Q40407741)

20 September 2017

title

Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways (English)

1 reference

20 September 2017

K McEvers

1

1 reference

20 September 2017

M Elrefaei

2

1 reference

20 September 2017

P Norris

3

1 reference

20 September 2017

S Deeks

4

1 reference

20 September 2017

J Martin

5

1 reference

20 September 2017

Y Lu

6

1 reference

20 September 2017

H Cao

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

15 April 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

23

1 reference

20 September 2017

issue

32

1 reference

20 September 2017

page(s)

4128-4135

1 reference

Purification of the third factor of anthrax toxin

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Identification of the cellular receptor for anthrax toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Crystal structure of the anthrax toxin protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Translocation of Bacillus anthracis lethal and oedema factors across endosome membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Characterization of membrane translocation by anthrax protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

CD4(+) T helper cells and the role they play in viral control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

CD4 T cell-dependent CD8 T cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Cytotoxic T lymphocytes: all roads lead to death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Cellular immune responses to HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Immunopathogenesis and immunotherapy in AIDS virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Disappointing data scuttle plans for large-scale AIDS vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.022

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.03.022

1 reference

release_d2xeu5gqb5agdhgtthcsbals7q

20 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d2xeu5gqb5agdhgtthcsbals7q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference